← Back to Search

Live Donor Advocacy Training + Social Media for Kidney Failure (ENGAGE Trial)

N/A
Waitlist Available
Led By Andrew Cameron, MD PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants at Northwestern University must speak English or Spanish.
Kidney transplant candidates aged≥18 added to the waitlist in the last year with no potential live donors are eligible.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 6 months of enrollment
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new educational intervention and mobile health intervention for people with end stage renal disease who don't have a potential live donor yet.

Who is the study for?
This trial is for adults over 18 with end-stage renal disease (ESRD) who've been on the kidney transplant waitlist in the past year without a live donor. It's open to English speakers at Johns Hopkins and University of Alabama, and English or Spanish speakers at Northwestern University.
What is being tested?
The study tests an educational program plus a Facebook app versus just the app to see if they help ESRD patients find kidney donors. The goal is to check how well these methods work in helping patients get live donors.
What are the potential side effects?
Since this trial involves education and use of social media rather than medical treatments, there are no direct medical side effects. However, participants may experience emotional or psychological impacts from engaging with social media.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I speak English or Spanish.
Select...
I am over 18, need a kidney transplant, and have no live donors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 6 months of enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 6 months of enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Live donor kidney transplantation
Secondary study objectives
Live Donor Inquiries
comfort initiating conversations
knowledge of live donation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Standard of CareActive Control1 Intervention
Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
Group II: Live Donor Champion + Facebook AppActive Control1 Intervention
The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
Group III: Facebook AppActive Control1 Intervention
The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.

Find a Location

Who is running the clinical trial?

Northwestern UniversityOTHER
1,649 Previous Clinical Trials
957,996 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,455 Previous Clinical Trials
4,334,333 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,332 Previous Clinical Trials
14,874,125 Total Patients Enrolled
University of Alabama at BirminghamOTHER
1,647 Previous Clinical Trials
2,341,750 Total Patients Enrolled
Andrew Cameron, MD PhDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
1,000 Total Patients Enrolled

Media Library

Facebook App Clinical Trial Eligibility Overview. Trial Name: NCT03099434 — N/A
Kidney Disease Research Study Groups: Standard of Care, Live Donor Champion + Facebook App, Facebook App
Kidney Disease Clinical Trial 2023: Facebook App Highlights & Side Effects. Trial Name: NCT03099434 — N/A
Facebook App 2023 Treatment Timeline for Medical Study. Trial Name: NCT03099434 — N/A
~89 spots leftby Dec 2025